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Abstract
This report describes the clinical courses of two acute myeloid leukemia patients. Both had MLL translocations, the
first a t(10;11)(p11.2;q23) with MLL-AF10 and the second a t(11;19)(q23;p13.1) with MLL-ELL fusion. They achieved a
clinical remission under conventional chemotherapy but relapsed shortly after end of therapy. Both had a history of
invasive mycoses (one had possible pulmonary mycosis, one systemic candidiasis). Because no HLA-identical donor
was available, a haploidentical transplantation was performed in both cases. Using a specially designed PCR
method for the assessment of minimal residual disease (MRD), based on the quantitative detection of the individual
chromosomal breakpoint in the MLL gene, both patients achieved complete and persistent molecular remission
after transplantation. The immune reconstitution after transplantation is described in terms of total CD3
+/CD4
+,
CD3
+/CD8
+, CD19
+,a n dC D 1 6
+/CD56
+ cell numbers over time. The KIR and HLA genotypes of donors and recipients
are reported and the possibility of a KIR-mediated alloreactivity is discussed. This report illustrates that haploidentical
transplantation may offer a chance of cure without chronic graft-versus-host disease in situations where no suitable
HLA-identical donor is available even in a high-risk setting and shows the value of MRD monitoring in the pre- and
posttransplant setting.
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Background
Acute myeloid leukemia (AML) is a molecularly hetero-
geneous disease. Around 5–10% of affected patients
show MLL translocations and an additional 8% have a
MLL partial internal duplication. While MLL aberrations
have historically and generally been associated with an
adverse prognosis, this view has become more differen-
tiated during recent years and at least for some rarer
MLL aberrations this verdict appears to be unfounded
[1]. The 5 most common MLL aberrations in adult AML
are t(9;11)/MLL-AF9, t(6;11)/MLL-AF6, t(11;19)/MLL-
ELL, t(11;19)/MLL-ENL, and t(10;11)/MLL-AF10, to-
gether accounting for around 80% of cases [2,3]. The
general recommendation for younger and medically fit
AML patients is allogeneic transplantation. The only ex-
ception are the core-binding factor leukemias with either
CBFA2-ETO or CBFB-MYH11, and acute promyelocytic
leukemia with PML-RARA, if no additional high-risk fea-
tures (e.g. FLT3-ITD) are present. Around 15–30% of
patients referred for transplantation have a suitable
HLA-identical sibling donor. Large donor registries can
be accessed for those patients without a HLA-identical
sibling donor, but the likelihood of finding a suitable
donor depends strongly on the ethnic background of the
patient [4]. Currently it is possible to identify a suitable
HLA-identical donor in around 70% of patients of Euro-
pean ancestry [5]. Different options exist for those
patients without a fully (10/10) HLA antigen-matched
donor. Clinical trials with donors showing only a 9/10,
8/10 or even 7/10 HLA match have shown a
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due to the higher incidence of severe graft-versus-host
disease (GvHD) [6-8]. The Perugia group of Martelli and
coworkers first introduced the concept of transplanting
“megadoses” of highly purified CD34
+ cells of a HLA-
haploidentical donor in the clinical setting to overcome
the HLA barrier and prevent graft failure [9,10]. To
achieve an alloreactive antileukemic effect in the absence
of alloreactive T-cells, donor-derived natural killer (NK)
cells were infused [11].
This report describes the clinical courses of two
patients with MLL-rearranged AML and particular high
risk features (early relapse, invasive mycoses) with par-
ticular emphasis on the MRD monitoring method which
was based on the quantitative detection of the individual
chromosomal breakpoints in the MLL gene. Both
patients had no suitable HLA-identical donor and thus
haploidentical transplantations were performed. The im-
mune reconstitution after transplantation in terms of B-
cells, CD4
+ and CD8
+ T-cells and NK cells is described.
Case presentation
Case 1
Features at presentation
A 33-year-old male patient was diagnosed with acute mye-
loid leukemia. The first clinical symptoms were dyspnoea
on exertion, a generalized maculopapular rash, gingival
hyperplasia, and general weakness. The blood count at
diagnosis revealed 52/nl leukocytes (79% blasts) a
hemoglobin of 11.1 g/dl (hematocrit 0.33), and platelets of
110/nl. The LDH was 1306 U/l (normal<248 U/l), cre-
atinine 1.27 mg/dl, C-reactive protein 16.1 mg/dl (normal
<0.5 mg/dl). Bone marrow cytology revealed an increased
overall cellularity and an 80% infiltration by medium-sized
blasts with basophilic cytoplasm, partial cytoplasmic
vacuolisation, prominent nucleoli, and positive esterase
staining, compatible with acute myeloid leukemia of the
FAB M5a subtype (Figure 1). Flow cytometric analysis of
the bone marrow revealed an expression of myeloid anti-
gens and HLA-DR with aberrant CD4 and CD56 expres-
sion. Cytogenetic analysis revealed a 46,XY,t(10;11)(p11.2;
q23) karyotype and molecular analysis by RT-PCR an
MLL-AF10 fusion transcript.
Initial treatment
The patient was randomized into arm C of the German
AML2003 study after informed consent. The study
protocol comprises two cycles DA (100 mg/m
2=200 mg
cytarabine continuously, d1-7+60 mg/m
2=120 mg dau-
norubicine, d3-5) followed by 3 cycles post-remission
therapy (MAC-MAMAC-MAC) with MAC=2×1 g/m
2
cytarabine d1-6+10 mg/m
2 mitoxantrone d4-6 and
MAMAC=2×1 g/m
2 cytarabine d1-5+100 mg/m
2 amsa-
crine d1-5. An allogeneic transplant is recommended after
completion of the first two cycles, if a donor is available.
However, no HLA-identical sibling or unrelated donor
could be identified in this case.
The inital clinical course was complicated by severe
adverse events. During the first days of DA induction
the patient suffered from acute dyspnea which led to his
admission to the intensive care unit where he first
received CPAP (Continuous Positive Airway Pressure)
and then mechanical ventilation. A thoracic CT scan
showed bilateral pleural effusions and atypical infiltrates.
During these first days right-sided hemiplegia and deso-
rientation developed. A cranial CT scan showed a left
frontal and right pareto-occipital parenchymal bleeding.
The renal function deteriorated and hemodialysis had to
be performed. The clinical situation improved under
broad-spectrum antibiotic treatment, the mechanical
ventilation and hemodialysis could be discontinued and
after 24 days on the ICU the patient was readmitted to
the ward. The patient made a full recovery under inten-
sive physical therapy with no residual neuro-psychiatric
deficits. A bone marrow biopsy on day 15 after start of
therapy showed a partial remission with around 10 to
20% blasts, and a second bone marrow biopsy on day
27, i.e. after leukocyte and platelet recovery, showed
cytologically a suspicious residual blast population; how-
ever, flow cytometry did not confirm a significant blast
population. The second induction cycle started on day
34 and had less adverse events. However, the patient
developed febrile neutropenia and a methicillin-resistant
Staphylococcus aureus (MRSA) was isolated from a
blood culture. Despite receiving antibiotic treatment
according to the resistogram, the patient developed
pneumonic infiltrates and increasing C-reactive protein
levels which only improved after a combination of vori-
conazole and liposomal amphotericin was added to the
antibiotic regimen. After leukocyte recovery all symp-
toms rapidly resolved and the patient could be dis-
charged with a prophylactic posaconazole medication.
The therapy was continued with 3 consolidation cycles
(MAC-MAMAC-MAC). Stem cells apheresis was per-
formed after the second consolidation cycle. Complica-
tions during consolidation included reactivation of the
pulmonary mycosis and a marked cervical lymphaden-
itis. Bone marrow cytology after each cycle showed a
complete remission.
Assessment of minimal residual disease (MRD)
A patient-specific PCR for detecting minimal residual
disease (MRD) was established as described previously
[12]. The chromosomal breakpoint in the MLL gene was
identified by long distance inverse PCR [13] and a highly
sensitive quantitative PCR using a hydrolysis probe for
detecting this breakpoint sequence was established [12]
(Figure 2). The maximal sensitivity was 10
-5 and the
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according to van der Velden [14]). This PCR showed con-
tinuously decreasing MRD which was below the detection
limit after the second and third consolidation cycle
(Figure 1).
Relapse and salvage therapy
Three and a half months after end of the therapy the pa-
tient presented with an inguinal swelling. A biopsy and a
bone marrow investigation was undertaken. The inguinal
biopsy revealed an extramedullary AML relapse. While
bone marrow cytology appeared normal, MRD investiga-
tion showed MRD positivity (Figure 2). A second bone
marrow investigation two weeks later confirmed the re-
lapse. In addition, patchy skin infiltrates appeared. The
patient was treated according to the Mito-FlAG scheme
(2×15 mg/m
2 fludarabine; 2×1000 mg/m
2 cytarabine d1-
5; 7 mg/m
2 mitoxantrone d1,3,5). The treatment was
relatively well-tolerated and besides a venous catheter-
associated S. epidermidis bacteriaemia, no major compli-
cations occurred. After therapy the patient achieved
complete cytomorphologic remission, the extramedullary
manifestations had disappeared and no MRD was detect-
able in the bone marrow.
Haploidentical transplantation
Since no HLA-identical donor was available, the haploi-
dentical mother of the patient was chosen as stem cell
donor. After successful eligibility assessment she under-
went stimulation with filgrastim (2×10 μg/kg body
weight) on days −5 to +1 and CD34
+ stems cells were
apheresed via an inguinal shaldon catheter on days 0
and +1. The patient was conditioned in parallel with
5 mg/kg thiotepa on day −9 and −8, 40 mg/m
2 fludara-
bine on day −7t o−4 and fractionized 12 Gy total body
irratiation on days −3t o−1 (Figure 3). Muromonab was
given daily in a dose of 5 mg on days −9 to +3. The
apheresed stem cells were T-cell depleted and 9.6 × 10
6
CD34
+ donor cells/kg recipient body weight were
infused on days 0 and +1. The infusion of donor NK
cells which had been scheduled for day +1 was post-
poned because of a relatively high CD3
+ cell count
(19.6×10
3/kg=1.5×10
6 in total) and concern regarding
severe graft-versus-host disease. The collected NK cells
were archived in liquid nitrogen. The conditioning re-
gime was tolerated relatively well. The clinical course
after transplantation was characterized by infectious
complications which could however be controlled with
adequate antibiotic treatments, e.g. a CMV reactivation
on day +27, which was successfully treated with valgan-
ciclovir. The leukocyte count was >1/nl since day +8
and the platelet count reached values >50/nl after
day +13. No signs of GvHD grade >1 were noted after
transplantation and thus it was decided to infuse the with-
held donor NK cells on day +27. No GvHD occurred after
this infusion.
Long-term follow-up and immune reconstituion
The further clinical course was uneventful and required
no hospitalizations. MRD follow-ups for almost three
years showed no persistent leukemia and the patient
returned to normal life working in his former profession
and is now, 4 years after transplantation, clinically free
of disease. Lymphocyte subpopulations were measured
in the peripheral blood at different time points after
transplantation (Figure 4). The T helper cell count
was>200/μl after day +104. Around day +104, a sharp in-
crease in CD8
+ cells was observed, however this could not
be related to any clinical event. All cell subsets increased to
normal values over time.
Case 2
Features at presentation (relapse)
A 28-year-old female patient was admitted to our hos-
pital after diagnosis of relapsed acute myeloid leukemia.
She had been diagnosed with AML FAB M2 16 months
earlier and had been treated elsewhere according to the
AML2003 protocol (see above) arm B with two cycles of
DA induction therapy and 3 cycles of high-dose
Figure 1 A. Bone marrow smear at diagnosis from the first
patient at two different magnifications. The marrow shows
increased cellularity by round-shaped medium-sized blasts with
basophilic occasionally vacuolated sparsely granulated cytoplasm
and perinuclear halos. The nuclei show 1-3 nucleoli. Peroxidase stain:
10% positive, esterase stain: 100% markedly positive, PAS stain:
approx. 50% granular positive. The cytomorphology is compatible
with the diagnosis of AML FAB M5a. B. Bone marrow smear at the
time of relapse from the second patient at two different
magnifications. The marrow shows an overall normal cellularity and
is infiltrated by heterogenous blasts displaying oval or bean-shaped
nuclei with prominent nucleoli and a moderately abundant partially
granulated cytoplasm. Peroxidase stain: 20% of blasts positive,
esterase stain negative. The cytomorphology is compatible with the
diagnosis of AML FAB M2.
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2 d1,3,5) consolidation therapy.
Cytological bone marrow examinations revealed a
delayed blast clearance (persistence on day 15 of first in-
duction, blast clearance after second induction). No
HLA-identical sibling or unrelated donor was available.
On presentation in our hospital she was in good overall
condition. The blood count showed 3.3/nl leukocytes
(30% blasts), 10.1 g/dl hemoglobin (0.29 hematocrit) and
79/nl platelets. The clinical chemical parameters and
LDH were otherwise normal. Bone marrow examination
confirmed the relapse (Figure 5). Cytogenetic analysis
showed a t(11;19)(q23;q13.1) which had also been
detected at the time of primary diagnosis. A MLL-ENL
fusion transcript was detected by RT-PCR.
Salvage treatment and disseminated candidiasis
The patient was treated according to a modified FlAmsa
protocol (30 mg/m
2 fludarabine d1-4, 100 mg/m
2 amsa-
crine d1-4, 2000 mg/m
2 cytarabine). During the subsequent
aplasia she developed an increase in C-reactive protein to
around 30 mg/l (normal<0.5 mg/l) despite broad-
spectrum antibiotic treatment. A thoracic CT scan showed
s m a l lb i l a t e r a lp u l m o n a r ya n dh epatic lesions suggestive of
atypical or fungal pneumonia. An MR scan of the abdomen
showed hepatomegaly (22 cm craniocaudal diameter) with
multiple lesions in liver, spleen and kidneys, measuring up
to 8 mm in diameter. At the same time, an elevated Can-
dida antigen level was detected in the serum. The patient
was initially treated with liposomal amphotericin B and
later with voriconazole. A bronchoalveolar lavage revealed
100–1.000 colony-forming units/ml Candida dubliniensis
and a liver biopsy showed neither leukemic infiltrates nor
fungi. Candida dubliniensis was later also isolated from a
stool specimen. Systemic candidosis was diagnosed, the
antimycotic treatment was changed to caspofungin and
a f t e raf u r t h e ri n c r e a s ei nC a n dida antigen titer to micafun-
gin with liposomal amphotericin B. The manifestation in
lungs, liver, spleen and kidneys regressed and the C-reactive
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Figure 2 Minimal residual disease (MRD) course of patient 1 over time. Three further peripheral blood samples taken at months 25, 28 and
33 were also MRD-negative (not shown in this diagram). Below the chromosomal break region with PCR primers and hydrolysis probe indicated.
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leukocytic regeneration. Liposomal amphotericin was dis-
continued 11 days before transplantation and micafungin
was continued until day +31 after transplantation after
which it was replaced by posaconazole. The candidiasis
delayed the scheduled transplantation by about 4 weeks.
Minimal residual disease was assessed by quantifying
the patient-specific chromosomal breakpoint sequence in
the MLL gene as described in the first case. A real-time
quantitative PCR was established and every bone marrow
specimen was investigated for MRD. The MRD level be-
fore transplantation was 10
-2 relative to the time of relapse
(Figure 5).
Haploidentical transplantation
The younger brother of the patient was chosen as a suitable
haploidentical stem cell donor. The conditioning regimen
for haploidentical was similar to that described above but
the 12 Gy total body irradiation was applied before the
chemotherapy for logistical reasons (Figure 1). A bone mar-
row investigation shortly before start of conditioning
revealed an MRD level of 10
-2,w h i c hw a so n l ys l i g h t l y
higher compared to that achieved one month ago after
FlAmsa therapy (Figure 1). The patient received a high
stem cell dose (15.87 × 10
6/kg body weight) from the donor
( T a b l e s1 ,2 ,a n d3 ) .O nd a y+ 1a f t e rC D 3 4
+ cell transplant-
ation donor NK cells (5.46 × 10
6/kg) were infused. The
clinical course after transplantation was relatively uncom-
plicated. In particular, there were no signs of recurrence of
invasive fungal infection under continuous daily micafungin
medication. The patient showed a mild graft-versus-host
reaction (grade 1) of the skin and intestine (both not histo-
logically verified) which regressed without immunosuppres-
sion. Clinical engraftment of leukocytes (>1/nl) and
platelets (>50/nl) occurred on day +10 and +13.
Immune reconstitution and MRD after transplantation
The MRD level was continuously negative in all investi-
gations after transplantation during the follow-up period
of more than one year (Figure 5). Immune reconstitution
occurred relatively fast, and T helper cells first reached a
level of >200/nl on day +36. A peak in CD8
+ cells was
observed on day +49 followed by a peak in CD8
+ cells
on day +58.
Conclusions
Haploidentical transplantation and the possible role of
KIR mismatches
The difficulties in finding a suitable HLA-identical donor
for every patient in need for it led to the idea of considering
the “always present but overlooked” [6] haploidentical rela-
tives as potential donors. The patient’s parents and children
are always HLA-haploidentical and the probability of a
patient’s sibling being HLA-haploidentical is 50% in con-
trast to 25% probability for full HLA identity. Thus
in practical reality the probability of finding a HLA-
haploidentical relative is nearly 100%.
Two major problems have to be overcome in haploiden-
tical transplantation: the first is graft rejection and the sec-
ond is severe graft-versus-host disease. The group of
Martelli et al. first demonstrated clinically that this is pos-
sible by using large amounts (“megadoses”,i . e .> 10
7/kg)
of highly purified CD34
+ hematopoietic stem cells. These
purified stem cells are largely devoid of T-cells which are
responsible for the graft-versus-host effect.
To achieve some kind of alloreactivity against residual
recipient’s blood cells, donor-derived natural killer (NK)
cells have been infused. The basis of this NK alloreactiv-
ity is not fully understood. NK cells are able to attack
other cells that show downregulation of HLA class I
molecules on their surface which is often the case in
-11 -10 -9 -8 -7 -6 -5 -4 -3 -2 -1
patient 2
patient 1
-12 0 +1 +2 +3
5 mg/kg thiotepa 2x2 Gy total body irradiation
40 mg/m  fludarabine
2 5 mg muromonab (OKT3)
CD34
day
CD56
+4 +5 +55 ..........
CD56
+
+
+
Figure 3 Conditioning regimens for haploidentical transplantation. For logistical reasons the irradiation was applied either before or after
the chemotherapy. Stem cells were infused on day 0 in both patients. The second patients received donor-derived NK cells on day +1. In the first
patient, NK cells were withheld until day +55 because of concerns regarding graft-versus-host disease due to the relatively high CD3+ cell
content.
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downregulation is neither necessary nor sufficient for
NK cell activation as is illustrated by the fact that nor-
mal cells or tissues lacking HLA class I expression
(e.g., erythrocytes) or showing low HLA class I ex-
pression (e.g., neural cells) are not attacked by autologous
NK cells. Cytotoxic NK cell activity is believed to be mainly
determined by the presence of inhibitory or activating
receptors on the NK cell surface. Two major types of in-
hibitory receptors have been identified: killer cell
immunoglobulin-like (KIR) receptors and the CD94/
NKG2A heterodimer, a C-type lectin, which interacts with
the non-classical class Ib HLA-E molecule (reviewed in
[15]). While the ligands for many KIR receptors are un-
known, the inhibitory receptors KIR2DL1, KIR2DL2 and
KIR3DL1 bind epitopes of HLA-C (’HLA-C2, -C1’ groups)
and HLA-A and HLA-B molecules with ’Bw4” motif,
respectively [16]. Upon encountering self-class HLA anti-
gen, NK cell–mediated lysis and cytokine release are
inhibited.
While HLA genes are located in the MHC complex on
chromosome 6p21.3, KIR genes are clustered in the
leukocyte receptor complex (LRC) on chromosome
19q13.4. Thus they segregate independently in human
pedigrees. The LRC is highly polymorphic and contains
seven to 15 KIR gene loci dispersed within a region of
65 to 200 kb [17]. It is not yet fully understood how NK
cells are “educated” not to attack other autologous cells
lacking inhibitory HLA ligands for their KIR receptors
[18,19]. Various models have been proposed to explain
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Figure 4 Immune reconstitution after transplantation in terms of B cells (CD19
+), cytotoxic T cells (CD3
+CD8
+), T helper cells
(CD3
+CD4
+) and NK cells (CD56
+). The first patient showed a sharp peak in CD8+ cells on day +104 (77 days after NK cell infusion) and the
second patient showed the same phenomenon on day +49 (48 days after NK cell infusion), followed by a peak in NK cells. The first patient may
also have had the NK peak, but it was possibly missed due to wider monitoring intervals. The peaks could not be correlated with clinical events.
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The “licensing model” predicts that NK cells that do not
receive a signal through an inhibitory receptor become
hyporesponsive instead of alloreactive. The “Ruggieri
model” assumes that NK cells with inhibitory KIR recep-
tors for ligands absent on both donor and recipient are
nonalloreactive. The effect of NK cell alloreactivity in
the setting of a fully HLA-matched transplantation has
been controversially discussed (synopsis in [16]). Some
groups have found a benefit in overall survival in case of
a KIR-HLA class I mismatch [20], but others could not
confirm this and found no effect [21] or even a worse
Table 1 Immunogenetic characteristics (HLA and KIR genotypes)
Recipient HLA Donor HLA Recipient KIR Donor KIR
case
1
A*0101, A*0301,B*1801,
B*4101, Cw*0102, Cw*1701,
DRB1*0301, DRB1*1301,
DQB1*0201, DQB1*0603
A*0101, A*2902,B*1801,
B*4403, Cw*0102, Cw*1601,
DRB1*0301, DRB1*0701,
DQB1*0201, DQB1*0202
2DL1+, 2DL2+, 2DL3-, 2DL4+, 2DL5+, 2DP1
+, 2DS1 +, 2DS2+, 2DS3+, 2DS4-, 2DS5-,
3DL1+, 3DL2+, 3DL3+, 3DP1+, 3DS1+
(2DS4 could not be excluded).
2DL1+, 2DL2+, 2DL3+, 2DL4+, 2DL5-,
2DP1+, 2DS1-, 2DS2+, 2DS3-, 2DS4+,
2DS5-, 3DL1+, 3DL2+, 3DL3+, 3DP1+,
3DS1+
case
2
A*0201, A*2601,B*4403,
B*5701, Cw*0401, Cw*0602,
DRB1*0402, DRB1*0701,
DQB1*0201, DQB1*0302
A*0201, A*6801,B*1302,
B*4402,Cw*0501, Cw*0602,
DRB1*0401, DRB1*0701,
DQB1*0201, DQB1*0301
2DL1+, 2DL2-, 2DL3+, 2DL4+, 2DL5+, 2DP1
+, 2DS1+, 2DS2-, 2DS3-, 2DS4+, 2DS5+,
3DL1+, 3DL2+, 3DL3+, 3DP1+, 3DS1+
2DL1+, 2DL2-, 2DL3+, 2DL4+, 2DL5+,
2DP1+, 2DS1+, 2DS2-, 2DS3-, 2DS4+,
2DS5+, 3DL1+, 3DL2+, 3DL3+, 3DP1
+, 3DS1+
Patient 2 was serologically HLA-haploidentical to her donor. However, high resolution DNA typing and HLA typing of the patient’s father revealed that donor and
patient had inherited different HLA haplotypes from their parents and were coincidentially nearly haploidentical (haploidentity apart from one molecular B44
mismatch).
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Figure 5 Minimal residual disease (MRD) course of patient 2. The last examined sample was taken from peripheral blood (pb). Below the
chromosomal break region with primers and hydrolysis probe indicated.
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Perugia group has published evidence that NK cells with
a mismatch between donor KIR and recipient's HLA
molecules in graft-versus-host direction positively cor-
relate with outcome at least in patients with myeloid
leukemias [10,11].
Both our patients and their donors showed inhibitory
and activating KIR genes corresponding to KIR haplo-
type group B. KIR ligands and mismatches were calcu-
lated using the EMBL IPD-KIR database release 2.4.0
[23]. Both donors were KIR3DL1-positive but only the
second patient had the corresponding inhibitory recep-
tor Bw4 (B44 and B57 with Bw4). The donor of patient
1 expressed KIR2DL2, 2DL3, 2DS2, 2DL1 and 2DS2, all
of which are ligands for Cw1 und Cw17, which were
expressed by patient 1. The first patient showed mis-
matches in both directions, a mismatch in GvH direc-
tion (donor KIR3DL1-based) and a mismatch in HvG
direction (recipient KIR2DL1-based). The second patient
showed neither a mismatch in GvH nor HvG direction.
Since no functional tests were performed it was not pos-
sible to assess any NK cell-based alloreactivity in both
cases.
Minimal residual disease before and after transplantation
Due to the extraordinary genetic heterogeneity of AML,
it is difficult to set up general recommendations for mo-
lecular monitoring of residual disease (recently reviewed
by [24-26]). Astonishingly few studies have addressed
the issue of MRD monitoring before and after allogeneic
transplantation in AML. Although the same MRD levels
may have a different prognostic impact in “good risk”
and “bad risk” AML, there is little doubt that the level of
molecular remission is in principle of critical importance
for the probability of long-term remission and the risk
of relapse. The issue how often and when to assess MRD
in AML is still controversial, but attempts have been
made to provide general recommendations for MRD
monitoring [24]. Basically two different methods have
been used for MRD assessment, polymerase chain reac-
tion (PCR) and flow cytometry. The main advantage of
flow cytometry is the speed of getting results; however,
disadvantages of the method are the lack and principal
difficulties in standardization. The theoretical maximum
achievable sensitivity is higher for flow cytometry than
PCR, but in reality it is often significantly lower. To ob-
tain a higher sensitivity, multiparameter flow has to be
used, but this again makes the procedure more compli-
cated and investigator-dependent. PCR is based on the
quantitative detection of clonal markers which are often,
but not necessarily, also disease markers, such as
leukemogenic fusion genes. In lymphoid neoplasms the
clonally rearranged immune genes of the malignant
clone can often be used as an MRD target. They are no
disease but surrogate markers and may sometimes get
lost during the course of disease due to further immune
gene rearrangements. Detection of MRD by PCR can be
based on RNA or DNA targets. RNA targets, such as
chimeric transcripts originating from leukemogenic fusion
genes, can often be assessed more easily, but MRD detec-
tion based on such RNA molecules has the disadvantage
that no absolute quantification is possible. Instead the
quantification is calculated relative to a “housekeeping
gene” or “control gene” which is supposed to be stably
expressed; of course this can only be an approximation. Be-
sides that, RNA is relatively unstable and degrades easily if
not stored at low temperatures. In contrast, DNA is re-
markably stable, usually over several days at room
temperature. PCR methods based on the quantification of
DNA targets allow a precise absolute quantification of the
target. It is not trivial to find such a clonal PCR target in
every case of AML. However, in acute leukemia with MLL
translocation it is possible and feasible to use the chromo-
somal breakpoint in the MLL gene as a molecular marker
for PCR [12]. The resulting PCR usually has a very high
sensitivity and stability. The MLL breakpoint can relatively
easily and elegantly be identified using a generic inverse
PCR method [13].
Sixteen AML patients at our institution received a haploi-
dentical stem cell transplant in the time period between
2004 and 2011, mostly because no suitable HLA-identical
donor was available, but in a few cases also because of
relapse after HLA-identical stem cell transplantation.
Fifteen out of the sixteen patients were transplanted with
Table 3 NK cell doses
Total WBC (10
6) CD56
+ count (10
6), total and per kg CD56
+content CD3
+ count (10
3), total and per kg
case 1 659 337 (4.32/kg) 51% 1530 (19.6/kg)
case 2 375 284.5 (5.46/kg) 91.6% 740 (14.0/kg)
Table 2 CD34
+ cells transplant characteristics
Total WBC (10
6) CD34
+ count (10
6), total and per kg CD34
+purity CD3
+ count (10
3), total and per kg CFU (10
5/kg)
case 1 770 753 (9.6/kg) 97.8% 548 (7.0/kg) 13.7
case 2 833 825.5 (15.87/kg) 99.5% 374 (8.0/kg) 28.2
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vival was 24% with a median follow-up of 3.7 years (detailed
data soon to be published). Several factors may have con-
tributed to the favourable outcome despite several risk fac-
tors in our two patients. First, both were relatively young
and had virtually no comorbidities. Second, in spite of early
relapses, the leukemias were still chemotherapy-sensitive
and responded relatively well to salvage therapy. Third, the
MRD niveau before transplantation was not very high. A
high pre-HCT MRD level has been associated with an
increased risk of relapse after myeloablative HCT for AML
[27]. Last but not least the regular MRD assessments were
certainly helpful to guide therapeutical decisions during the
course of disease.
In short summary, the two cases presented here illus-
trate the value of regular MRD monitoring in the pre-
and post-transplant setting for guiding clinical decisions.
They show exemplarily the immune reconstitution after
haploidentical transplantation and illustrate that under
certain circumstances haploidentical transplantation may
be an option even for patients with a history of invasive
fungal infections.
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